Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication?
- PMID: 8449079
- DOI: 10.1378/chest.103.3.844
Thrombotic lesions in primary plexogenic arteriopathy. Similar pathogenesis or complication?
Abstract
In 78 patients with primary plexogenic arteriopathy (PPA), numbers of organized and recanalized thrombi were established in histologic slides of lung tissue and expressed per square centimeter of section. Three control groups of ten individuals each were used: normal, plexogenic arteriopathy secondary to ventricular septal defect, and hypoxic pulmonary hypertension. Thrombotic lesions were scarce in normal individuals but numerous in all three groups with pulmonary hypertension. There is also a positive correlation with age. Thrombotic lesions are absent or scarce in children but more common in adults, even in normal control subjects and particularly in pulmonary hypertension by whatever cause. In PPA there is likely to be a relation with the duration of illness but not with the stage of the disease. The complete pattern of plexogenic arteriopathy may develop in the absence of thrombotic lesions, which clearly are not essential for its pathogenesis. Rather than being part specifically of PPA, as sometimes suggested, thrombotic lesions complicate various types of hypertensive pulmonary vascular disease. Apparently the combination of sustained pulmonary hypertension and age, possibly through endothelial injury, may elicit thrombosis and its sequelae, which in turn may aggravate the pulmonary arterial pressure.
Comment in
-
The role of thrombosis in pulmonary hypertension.Chest. 1993 Mar;103(3):660-1. doi: 10.1378/chest.103.3.660. Chest. 1993. PMID: 8449046 No abstract available.
Similar articles
-
Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients.Br Heart J. 1985 Oct;54(4):428-34. doi: 10.1136/hrt.54.4.428. Br Heart J. 1985. PMID: 4052282 Free PMC article.
-
Morphological substrate for the reversibility and irreversibility of pulmonary hypertension.Eur Heart J. 1988 Sep;9 Suppl J:7-12. doi: 10.1093/eurheartj/9.suppl_j.7. Eur Heart J. 1988. PMID: 3053185 Review.
-
Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension.Chest. 1986 May;89(5):694-8. doi: 10.1378/chest.89.5.694. Chest. 1986. PMID: 3698700
-
Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery.J Thorac Cardiovasc Surg. 1984 Jun;87(6):876-86. J Thorac Cardiovasc Surg. 1984. PMID: 6727410
-
Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment.J Am Coll Cardiol. 1989 Sep;14(3):545-50. doi: 10.1016/0735-1097(89)90090-9. J Am Coll Cardiol. 1989. PMID: 2671093 Review.
Cited by
-
Plexogenic arteriopathy.Thorax. 1994;49 Suppl(Suppl):S39-45. doi: 10.1136/thx.49.suppl.s39. Thorax. 1994. PMID: 7974326 Free PMC article. Review. No abstract available.
-
Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.Health Qual Life Outcomes. 2016 Jul 26;14(1):110. doi: 10.1186/s12955-016-0513-8. Health Qual Life Outcomes. 2016. PMID: 27460644 Free PMC article.
-
Angiopoietin-2 and D-dimer add prognostic information to clinical risk in pulmonary arterial hypertension.JHLT Open. 2024 Nov 6;7:100178. doi: 10.1016/j.jhlto.2024.100178. eCollection 2025 Feb. JHLT Open. 2024. PMID: 40144824 Free PMC article.
-
Current Approach to the Diagnosis and Management of Portopulmonary Hypertension.Curr Gastroenterol Rep. 2016 Jun;18(6):29. doi: 10.1007/s11894-016-0504-2. Curr Gastroenterol Rep. 2016. PMID: 27098816 Review.
-
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.Clin Pharmacol Ther. 2010 Mar;87(3):303-10. doi: 10.1038/clpt.2009.217. Epub 2009 Dec 9. Clin Pharmacol Ther. 2010. PMID: 20010555 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical